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ABSTRACT 
Background    Thymic stromal lymphopoietin (TSLP) 
plays an important role in promoting tumor survival, by 
manipulating the immune response and angiogenesis. 
However, the clinical significance of TSLP in gastric 
cancer is unclear.
Methods    Immunohistochemistry was used to investi-
gate TSLP expression in non-cancerous gastric mucosa 
and gastric cancer tissue from patients with gastric 
cancer. Serum TSLP levels were measured using an 
enzyme-linked immunosorbent assay.
Results    Tumors with TSLP expression were signifi-
cantly larger than those without TSLP expression. TSLP 
expression was observed more frequently in advanced 
(T2/T3/T4) than in early (T1) gastric cancer and in stage 
3/4 than in stage 1/2. Lymph node metastasis, liver me-
tastasis, positive peritoneal lavage cytology, lymphatic 
invasion, and vascular invasion occurred significantly 
more often in TSLP-expressing than in non-expressing 
tumors. The prognosis of patients with TSLP-positive 
tumors was significantly worse than that of patients with 
TSLP-negative tumors. Patients with high serum TSLP 
concentrations also had a significantly worse prognosis 
than those with low concentrations. Multivariate analysis 
identified serum TSLP level as an independent prognos-
tic indicator.
Conclusion    TSLP is closely related to the progression 
of gastric cancer and may predict survival in these pa-
tients.
Key words    Gastric cancer; Prognosis; TSLP; Tumor
Thymic stromal lymphopoietin (TSLP) is an interleu-
kin-7 (IL-7)-like cytokine originally identified by its 
ability to promote the proliferation and development 
of immature B cells.1 Several types of cells respond to 
TSLP, such as basophils,2 mast cells,3 B cells,4 CD4+,5 
CD8+,6 natural killer T cells,7 and dendritic cells (DCs).8 
Moreover, a major subset of TSLP-responsive cells iden-
tified in both humans8 and mice9 are myeloid-derived 
DCs that express high levels of TSLP receptor (TSLPR) 
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complex. This heterodimer of TSLPR and IL-7R alpha 
is functional and has a high affinity for TSLP.8
 CD4+ effector T cells play a central role in initiating 
and maintaining antitumor immunological responses. 
They are categorized into two subsets based on their 
cytokine profile. Thus, in mice and humans type 1 (Th1) 
or type 2 (Th2) have been identified.10, 11 Th1 cells pro-
duce interferon-gamma and mainly confer protection 
against microbial infections, whereas Th2 cells produce 
IL-4, -5, -9, and -13 and help protect against infections 
by gastrointestinal nematodes, but they are also respon-
sible for allergic disorders.12, 13 TSLP plays an extremely 
important role in the induction of Th2. TSLP-activated 
DCs are primed for inflammatory Th2 cell differentia-
tion through their expression of the OX40 ligand.14 Thus, 
dysregulated TSLP expression can result in the develop-
ment of type 2 inflammatory responses leading to aller-
gic disease.
 The Th2 response predominates over the Th1 re-
sponse not only in allergic disease but also in many 
types of cancers.15 Tumors associated with a Th2-type 
response generally carry a worse prognosis than those 
with a predominantly Th1-type response.16, 17 However, 
the mechanism by which Th2-biased immune responses 
are initiated in tumors is largely unknown. De Monte 
et al. recently demonstrated that in pancreatic cancer, 
TSLP produced by cancer-associated fibroblasts acti-
vates DCs to undergo Th2 differentiation.17 Pedroza-
Gonzalez et al. showed that TSLP produced by breast 
cancer cells was capable of inducing OX40 ligand 
expression in DCs, which in turn promoted Th2 differ-
entiation by naïve CD4+ T cells.18 These observations 
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suggest an important role for TSLP in promoting Th2-
biased immune responses in the tumor microenviron-
ment. Indeed, TSLP expression has been confirmed in 
several types of cancer, including breast cancer,19, 20 cer-
vical cancer,21 lung cancer,22 and leukemia,23, 24 and is 
associated with the progression and metastasis of these 
tumors.19–21
 Gastric cancer is one of the most common cancers in 
Asia and ranks second among all cancer deaths world-
wide.25 Helicobacter pylori infection promotes TSLP 
production by gastric epithelial cells and induces DC-
mediated inflammatory Th2-type responses,26 which 
have been shown to predominate in gastric cancer.27 
Since H. pylori infection is closely related to the onco-
genesis of gastric cancer, we hypothesized that TSLP 
expression similarly correlates with tumor progression 
and prognosis in these patients. Therefore, in this study 
the clinical significance of TSLP expression in patients 
with gastric cancer was determined by comparing their 
non-cancerous gastric mucosa and gastric cancer tissue 
and by measuring serum TSLP concentrations. 
MATERIALS AND METHODS 
Patients
One hundred and thirty-two and 110 patients who 
treated at Tottori University Hospital and pathologically 
diagnosed with gastric cancer were enrolled for immu-
nohistochemistry and Enzyme-Linked ImmunoSorbent 
Assay (ELISA), respectively, in the current study. None 
of the patients had received radiotherapy, chemotherapy, 
or other medical interventions before surgery. The clini-
copathological findings were determined according to 
the Japanese Classification of Gastric Carcinoma.28 This 
study was approved by the Ethical Committee of the 
Tottori University Hospital (approval number: 2573) and 
written informed consent was obtained from all patients. 
Immunostaining analysis
Serial sections (4 µm thick) were dewaxed in xylene, 
dehydrated in ethanol, placed in citrate buffer pH 6, 
and heated in a microwave oven (700 W) for 15 min to 
retrieve the antigens. The tissues were then incubated in 
3% hydrogen peroxide in methanol to block endogenous 
peroxide. Immunohistochemical staining for TSLP was 
performed using anti-human TSLP antibody (ab47943; 
Abcam, Cambridge, MA) at a dilution of 1:100 and a 
secondary antibody (ab97080; Abcam) at a dilution of 
1:200, according to the manufacturer’s instructions. The 
tissue sections were evaluated by a pathologist blinded 
to the clinical data and considered positive when > 10% 
of the cells expressed TSLP.
Measurement of serum TSLP level
Serum TSLP levels were measured in an ELISA using a 
human TSLP immunoassay (DY1398, R&D SYSTEMS, 
Minneapolis, MN). All samples were measured in dupli-
cate and the mean concentration was calculated.
Statistical analysis
Associations among factors were evaluated using the 
χ2 test. Mann-Whitney U-tests were used to determine 
statistical differences between groups. Five-year survival 
rates were calculated according to the Kaplan-Meier 
method and differences between survival curves were 
examined with the log-rank test. Survival data represent 
cancer-specific survival. Thus, patients who died from 
causes other than gastric cancer were considered lost to 
follow-up as of the time of death. Multivariate analysis 
was performed using the Cox proportional hazards mod-
el. The accepted level of significance was defined as a P-
value < 0.05. Statistical analyses were performed using 
SPSS Statistics 22.0 for Windows (IBM, Armonk, NY). 
RESULTS
TSLP expression in the tissue of non-cancerous 
gastric mucosa and gastric cancer
The immunohistochemically demonstrated expression of 
TSLP in non-cancerous gastric tissue and cancer tissue 
is shown in Fig. 1. TSLP expression was observed in the 
cytoplasm of cells from non-cancerous gastric mucosa 
obtained from 23 patients (20.9%) and in the cancer tis-
sues of 57 patients (51.8%). There was no significant cor-
relation between the clinicopathological characteristics 
of the patients and TSLP expression in non-cancerous 
gastric mucosa (Table 1). However, TSLP expression in 
the malignant tissue was associated with significantly 
larger tumors and occurred more frequently in advanced 
(T2/T3/T4) than in early (T1) gastric cancer and in stage 
3/4 than in stage 1/2 disease. Lymph node metastasis, 
liver metastasis, positive peritoneal lavage cytology, 
lymphatic invasion, and vascular invasion also occurred 
significantly more often in patients with TSLP-express-
ing cancer tissue (Table 1). 
The 5-year survival rates of patients with TSLP-positive 
tumors and TSLP-negative tumors were 21.8% and 
76.9%, respectively (P = 0.0011; Fig. 2). By contrast, 
there was no significant difference in the prognosis of 
patients with TSLP-positive and TSLP-negative non-
cancerous mucosa (P = 0.4; data not shown).
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(a) (b) (c)
Fig. 1. TSLP expression in non-cancerous gastric mucosa and gastric cancer tissue. (a) Non-cancerous gastric mucosa, × 400; (b) tubular 
adenocarcinoma, ×400; (c) poorly differentiated adenocarcinoma, × 400.
Table 1. TSLP expression in gastric cancer and the clinicopathological characteristics of the patients
TSLP expression
Non-cancerous gastric mucosa Cancer tissue
Negative Positive P-value Negative Positive P-value
Tumor size (mm) 48.8 ± 31.7 44.0 ± 29.5 0.430 42.8 ± 28.3 59.5 ± 34.3  0.023 
Age (years) 68.5 ± 10.2 64.8 ± 13.3 0.108 65.8 ± 12.4 69.4 ± 9.6  0.195 
  Male 42 34 0.026 63 14  0.283 
  Female 11 23 24 9
Histology
  Differentiated 30 27 0.333 41 16  0.055 
  Undifferentiated 23 30 46 7
Depth of invasion
  T1 27 29 0.994 52 4  < 0.001
  T2/T3/T4 26 28 35 19
Lymph node metastasis
  Absent 34 32 0.391 59 7  0.001 
  Present 19 25 28 16
Peritoneal metastasis
  P0 50 50 0.227 82 19  0.070 
  P1 3 7 5 4
Liver metastasis
  H0 49 55 0.351 87 17  < 0.001
  H1 4 2 0 6
Cytology
  CY0 31 36 0.600 55 11  0.016 
  CY1 5 4 5 5
Lymphatic invasion
  Absent 20 23 0.779 41 2  0.001 
  Present 33 34 46 21
Vascular invasion
  Absent 24 29 0.557 49 4  0.001 
  Present 29 28 38 19
Disease stage
  1/2 37 41 0.807 68 10  0.001 
  3/4 16 16 19 13
TSLP, Thymic Stromal Lymphopoietin. 
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Table 2. Serum concentration of TSLP in gastric  
cancer patients and their clinicopathologic  
characteristics
n TSLP (pg/mL) ± SD P-value
 Male 92 226.6 ± 583.8  0.741 
 Female 40 189.4 ± 614.5
Tumor size (mm)
 > 40 48 233.4 ± 705.3  0.576 
 < 40 66 170.5 ± 493.3
Histology
 Differentiated 67 194.5 ± 580.0  0.683 
 Undifferentiated 65 236.8 ± 606.2
Depth of invasion
 T1 67 165.3 ± 494.9  0.315 
 T2/T3/T4 60 272.6 ± 695.3
Lymph node metastasis
 Absent 86 226.8 ± 652.5  0.762 
 Present 46 193.9 ± 460.9
Lymphatic invasion
 Absent 53 133.1 ± 471.8  0.308 
 Present 66 242.5 ± 652.8
Venous invasion
 Absent 67 133.7 ± 447.2  0.200 
 Present 52 271.2 ± 712.2
Peritoneal metastasis
 P0 120 192.3 ± 577.3  0.152 
 P1 9 486.6 ± 770.3
Liver metastasis
 H0 126 169.7 ± 544.9  < 0.001
 H1 6 1173.6 ± 761.8
Peritoneal lavage cytology 
 CY0 74 172.1 ± 633.7  0.043 
 CY1 9 650.6 ± 870.8
Disease stage
 1/2 93 182.5 ± 587.5  0.326 
 3/4 39 293.7 ± 600.3
TSLP, Thymic Stromal Lymphopoietin.
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Fig. 2. Survival curves of gastric cancer patients according to 
TSLP expression in gastric cancer tissue.
TSLP, Thymic Stromal Lymphopoietin.
Fig. 3. Survival curves of gastric cancer patients according to 
their serum TSLP concentrations.
TSLP, Thymic Stromal Lymphopoietin.
Table 3. Association of prognostic factors with dis-
ease-specific survival in patients with gastric cancer, 
as determined by the Cox proportional hazards mod-
el
Prognostic factors Hazard ratio 95% CI P-value
Age* 1.035 0.972–1.102 0.280
Sex 0.444 0.105–1.874 0.269
Histology† 1.372 0.395–4.761 0.619
Depth of invasion(T1–T4) ‡ 2.569 0.861–7.666 0.091
Lymph node metastasis (n0–n3) § 1.023 0.494–2.118 0.951
Peritoneal metastasis (P0–P1) 2.214 0.131–37.286 0.581
Lymphathic invasion (ly0–ly3) || 1.889 0.763–4.677 0.169
Vascular invasion (v0–v3) ¶ 1.022 0.524–1.993 0.948
Tumor size* 1.010 0.990–1.030 0.342
TSLP concentration 1.001 1.000–1.002 0.003
*Continuous variable.
†Differentiated, papillary or tubular adenocarcinoma; undiffer-
entiated, poorly differentiated or mucinous adenocarcinoma, or 
signet-ring cell carcinoma.
‡T3, penetrating the serosa; T4, invading adjacent organs.
§n0–n3, grade of lymph node metastasis .
||Lymphatic invasion: ly0–ly3, grade of lymphatic vessel invasion
¶Vascular invasion: v0–v3, grade of vascular invasion.
CI, confidence interval; TSLP, Thymic Stromal Lymphopoietin.
Serum concentration of TSLP in gastric cancer 
patients
The serum concentration of TSLP was significantly 
higher in patients with than in those without liver metas-
tasis (P < 0.001; Table 2) and in patients with than with-
out intraperitoneal free cancer cells (P = 0.043; Table 2). 
The serum TSLP concentrations in patients with TSLP-
positive and TSLP-negative tumors were 178.2 ± 68.1 
and 155.0 ± 122.2 pg/mL, respectively; the difference 
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was not statistically significant (P = 0.39). Serum TSLP 
concentrations were 130.8 ± 54.1 and 217.5 ± 107.4 pg/
mL in patients with TSLP-positive and TSLP-negative 
non-cancerous tissue, respectively; again, the difference 
was not statistically significant (P = 0.14).
Based on a mean serum TSLP concentration in our gas-
tric cancer patients of 215.3 pg/mL, a cut-off value of 
200 pg/mL was used in this study to determine survival 
as a function of TSLP expression. The 5-year survival 
rates of patients with high (> 200 pg/mL) and low (≤ 
200 pg/mL) serum TSLP levels were 54.5% and 75.1%, 
respectively (Fig. 3). The patients with high serum TSLP 
concentrations also had a significantly worse prognosis 
than those with low concentrations (P = 0.023; Fig. 3). In 
a multivariate analysis, serum TSLP level was an inde-
pendent prognostic indicator (P = 0.003; Table 3).
Finally, we examined the correlation between the serum 
TSLP level and serum carcinoembryonic antigen (CEA) 
and carbohydrate antigen (CA) 19-9 levels. The latter 
are the most frequently used tumor markers in gastric 
cancer; however, there were no significant correlations 
between CEA, CA19-9, and TSLP expression (P = 0.96, 
P = 0.55, respectively; data not shown).
DISCUSSION
TSLP expression in both the non-cancerous gastric mu-
cosa and the cancer tissue of our patients with gastric 
cancer was demonstrated using immunohistochemistry. 
TSLP expression in gastric cancer tissue, but not in 
non-cancerous gastric mucosa, was found to correlate 
significantly with cancer progression. Furthermore, pa-
tients with TSLP-positive had slightly worse prognosis 
than those with TSLP-negative, but the reason for this 
relationship is as yet unknown. However, TSLP plays a 
very important role in the induction of the Th2-based 
immune response and previous studies have shown that 
the Th1/Th2 ratio is a prognostic indicator in gastric 
cancer patients.27 In addition, the polarization of group 
2 innate lymphoid cells, which produce large amounts 
of Th2 cytokines, contributes to the immunosuppressive 
microenvironment in gastric cancer.29 In cervical cancer, 
tumor-derived TSLP also act on TSLPR+ endothelial 
cells to promote angiogenesis.21, 30 Neo-angiogenesis is 
a critical process in cancer progression. In gastric cancer 
patients, high microvessel counts correlate significantly 
with a poor prognosis.31 Therefore, the TSLP-mediated 
increase in microvessels supplying the malignant tis-
sue of gastric cancer may explain the relation between 
TSLP and a poor prognosis. Alternatively, regulatory T 
cells (Tregs) may play a role, based on in vitro studies 
demonstrating the involvement of TSLP in the genera-
tion of tolerogenic DCs that drive the differentiation of 
Tregs.32–34 Kim et al. demonstrated that a higher intratu-
moral Tregs/helper T cells ratio was significantly related 
to poor prognosis in gastric cancer patients.35 Further 
investigations are needed to clarify the role of TSLP in 
the progression of gastric cancer.
 An analysis of the relationship between the serum 
concentration of TSLP and the prognosis of gastric can-
cer patients showed that patients with high serum TSLP 
concentrations had a significantly worse prognosis than 
low concentrations. The role of serum TSLP level as 
an independent indicator of prognosis in gastric cancer 
patients was confirmed in a multivariate analysis. Thus, 
the measurement of serum TSLP in patients with non-
invasive gastric tumors may provide important prog-
nostic information. However, the serum TSLP level was 
not related to the serum levels of two important tumor 
markers in gastric cancer, CEA and CA19-9. Therefore, 
measurement of the serum TSLP level may be useful to 
predict the prognosis of gastric cancer patients regard-
less of their serum CEA and CA19-9 concentrations. 
 To the best of our knowledge, ours is the first study 
to show a correlation between serum TSLP level and 
prognosis in gastric cancer patients. The absence of a 
relationship between TSLP expression in non-cancerous 
gastric mucosa, gastric cancer tissue, and the concen-
tration of serum TSLP contrasts with the high serum 
TSLP concentrations in patients with liver metastasis 
and peritoneal lavage cytology. These observations sug-
gest that TSLP is produced by tumor cells, fibroblasts, 
and epithelial cells at the metastatic site. In other words, 
TSLP expression reflects only a local progression of can-
cer, and serum TSLP reflects a systemic progression of 
cancer, such as metastasis and positive peritoneal lavage 
cytology. Because of this, we considered serum TSLP 
was only a prognostic indicator. The origin of the high 
concentration of serum TSLP remains to be determined. 
 There is currently no effective treatment for recur-
rent gastric cancer. Novel strategies for inhibiting tumor 
growth and thereby improving survival include the 
blockage of TSLP or OX40 ligand and thus IL-13 pro-
duction, an approach recently evaluated in a xeno trans-
fer model.36 However, the close relationship between 
TSLP and the progression of gastric cancer suggests that 
TSLP is a potentially important and effective target for 
the treatment of gastric cancer. Measurement of serum 
TSLP levels might improve survival predictions for pa-
tients with gastric cancer.
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